OSAKA UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1931-05-01

Employees: -

Market Cap: -

Website: http://www.osaka-u.ac.jp

Clinical Trials

229

Active:2

Completed:117

Trial Phases

5 Phases

Phase 1:12

Phase 2:14

Phase 3:1

+2 more phases

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (224 trials with phase data)• Click on a phase to view related trials

Not Applicable

191 (85.3%)

Phase 2

14 (6.3%)

Phase 1

12 (5.4%)

Phase 4

6 (2.7%)

Phase 3

1 (0.4%)

Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients

Not Applicable

Not yet recruiting

Conditions: Aortic Stenosis

First Posted Date: 2025-04-11

Last Posted Date: 2025-06-04

Lead Sponsor: Osaka University

Target Recruit Count: 800

Registration Number: NCT06924151

Locations: 🇯🇵
Nagoya Tokusyukai General Hospital, Kasugai, Aichi, Japan
🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Aichi, Japan
🇯🇵
New Tokyo Hospital, Matsudo, Chiba, Japan

and more 35 locations

TAV-in-SAV in Japanese Patients

Active, not recruiting

Conditions: Valve-in-valve Procedures

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Osaka University

Target Recruit Count: 180

Registration Number: NCT06826027

Locations: 🇯🇵
Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Chiba, Japan
🇯🇵
Osaka University, Suita, Osaka, Japan
🇯🇵
Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan

and more 7 locations

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: PSW-1025

First Posted Date: 2024-06-04

Last Posted Date: 2025-07-31

Lead Sponsor: Osaka University

Target Recruit Count: 15

Registration Number: NCT06441994

Locations: 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan

A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer

Interventions: Radiation: Radiation
Drug: Chemotherapy
Procedure: Surgery

First Posted Date: 2023-07-11

Last Posted Date: 2023-07-11

Lead Sponsor: Osaka University

Target Recruit Count: 45

Registration Number: NCT05939661

Locations: 🇯🇵
Osaka General Medical Center, Osaka, Japan
🇯🇵
Osaka University Hospital, Osaka, Japan

Evaluation of Postoperative Ventilation Distribution With Electrical Impedance Tomography

Conditions: Electrical Impedance Tomography

First Posted Date: 2022-05-25

Last Posted Date: 2022-05-25

Lead Sponsor: Osaka University

Target Recruit Count: 130

Registration Number: NCT05389735

Locations: 🇯🇵
Department of Anesthesiology and Intensive Care Medicine, Osaka University, Osaka, Japan

News

Alpha Fusion and Curadh Form Strategic Partnership to Advance Astatine-211 Radiopharmaceuticals

2 months ago

Alpha Fusion and Curadh MTR announced a strategic partnership including a joint venture to advance global development of Astatine-211 based radiopharmaceuticals for cancer therapy.